For patients with metastatic non-small cell lung cancer, when more than 50% of the tumour cells express the PD-L1 protein, the first-choice treatment is often monotherapy with pembroiizumab (an immunostimulatory antibody directed against the PD-1 receptor) (see also "Cemiplimab (Libtayo0) as first-line monotherapy for certain lung cancers" left). Atezolizumab, an immunostimulatory antibody directed against PD-L1 protein, has now also been authorised as first-line monotherapy in this situation, in particular when 50% or more of the tumour cells express the PD-L1 protein. This authorisation is based on a single clinical trial, the methodology of which was too biased to demonstrate an extension of median overall survival compared to platinum-based chemotherapy. The adverse effects of atezolizumab are similar to those of pembroiizumab.
展开▼
